In a phase I clinical trial of glioblastoma multiforme (GBM) (ClinicalTrials.gov ID: NCT01109095), researchers engineered HER2-CAR into T cells pre-selected for their ability to recognize cytomegalovirus (CMV). Here, ERBB2 is linked to glioblastoma.